Investing.com - Barclays reiterated an Overweight rating and $157.00 price target on BridgeBio Pharma (NASDAQ:BBIO). The firm estimates first-quarter U.S. Attruby revenue of $175 million versus ...
BridgeBio Pharma, Inc. (NASDAQ:BBIO) is one of the best high growth healthcare stocks to buy now. Mizuho lifted the price target on BridgeBio Pharma, Inc. (NASDAQ:BBIO) to $106 from $91 on March 18, ...
BridgeBio Pharma, Inc. (NASDAQ:BBIO) is one of the best high growth healthcare stocks to buy now. Mizuho lifted the price target on BridgeBio Pharma, Inc. (NASDAQ:BBIO) to $106 from $91 on March 18, ...
If you could inject yourself with a substance that purports to make you tanner, fitter and healthier, would you? Many people are saying “yes.” Online, social media influencers tout vials of substances ...
Barclays has reiterated its Overweight rating on the company, with expectations of first-quarter U.S. Attruby revenue reaching $175 million, surpassing the consensus estimate of $169 million. Total ...
Stocks extend relief rally on hopes that U.S.-Iran ceasefire will stick, Dow turns positive for 2026
Stocks extended their rally Thursday, even as oil prices gained, amid continued optimism among traders that the fragile two-week ceasefire between the U.S. and Iran could be sustained. The S&P 500 ...
- Earliest timepoint in an open-label extension with this magnitude of risk reduction at 44.7% in ACM (p<0.0001) and 49.3% in CVM (p<0.0001) -Acoramidis mitigated the rise in NT-proBNP through Month ...
Top insights from the latest market news from Tuesday, March 31, from The Motley Fool analysts on Team Rule Breakers and Team Hidden Gems. By The Motley Fool Team, Buck Hartzell, Karl Thiel, and Emily ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results